Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of dise

Trial Details

NCT ID

NCT06493552

Phase

PHASE2 / PHASE3

Sponsor

Vasgene Therapeutics, Inc

Status

RECRUITING

Cancer Type

Non-Muscle-Invasive Bladder Cancer

Interventions

SEphB4-HSA
Pembrolizumab
Gemcitabine
Cisplatin
Enfortumab vedotin

Locations (sample)

Santa Monica, California, United States|34.01949,-118.49138

Key Eligibility Criteria

General Inclusion Criteria for Both Arms
Willing and able to provide informed consent.
Men and women 18 years of age, or older.
Must provide the cell block or a minimum of 15 slides from the diagnostic biopsy or archival tissue.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →